DOCSLIB.ORG

Quick Release Pharmaceutical Compositions of Drug Substances

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Quick Release Pharmaceutical Compositions of Drug Substances Europäisches Patentamt *EP001109534B1* (19) European Patent Office Office européen des brevets (11) EP 1 109 534 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.7: A61K 9/16, A61K 9/20 of the grant of the patent: 12.02.2003 Bulletin 2003/07 (86) International application number: PCT/DK99/00480 (21) Application number: 99941418.8 (87) International publication number: (22) Date of filing: 10.09.1999 WO 00/015195 (23.03.2000 Gazette 2000/12) (54) QUICK RELEASE PHARMACEUTICAL COMPOSITIONS OF DRUG SUBSTANCES PHARMAZEUTISCHE ZUSAMMENSETZUNGEN MIT SCHNELLER FREISETZUNG VON WIRKSTOFFEN COMPOSITIONS A BASE DE SUBSTANCES MEDICAMENTEUSES A USAGE PHARMACEUTIQUE A LIBERATION RAPIDE (84) Designated Contracting States: • ITAI, Shigeru AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Ageo-shi, Saitama 362-0046 (JP) MC NL PT SE Designated Extension States: (74) Representative: Plougmann & Vingtoft A/S AL LT LV MK RO SI Sundkrogsgade 9, P.O. Box 831 (30) Priority: 10.09.1998 DK 981143 2100 Copenhagen O (DK) (43) Date of publication of application: (56) References cited: 27.06.2001 Bulletin 2001/26 WO-A-95/32737 WO-A-96/14839 (73) Proprietor: NYCOMED DANMARK A/S • CHEMICAL ABSTRACTS, vol. 116, no. 10, 9 4000 Roskilde (DK) March 1992 (1992-03-09) Columbus, Ohio, US; abstract no. 91424, NEMOTO, MASAMI ET AL: (72) Inventors: "Solid preparations with accelerating • BERTELSEN, Poul absorption of oxicam-type anti-inflammatory DK-2720 Vanlose (DK) agents for internal use" XP002095848 & JP 03 • HANSEN, Nils, Gjerl v 240729 A (TAISHO PHARMACEUTICAL CO., DK-2000 Frederiksberg (DK) LTD., JAPAN) • RUCKENDORFER, Hermann A-4193 Reichenthal (AT) Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention). EP 1 109 534 B1 Printed by Jouve, 75001 PARIS (FR) EP 1 109 534 B1 Description [0001] The present invention relates to an oral modified release pharmaceutical composition for the administration of a therapeutically and/or prophylactically effective amount of an active substance (a drug substance) to obtain a 5 relatively fast or quick onset of the therapeutic and/or prophylactic effect. The drug substances contained in a modified release pharmaceutical composition according to the invention are suitably a drug substance which has a very low solubiiity under acidic conditions, i.e. under conditions similar to those present in the stomach and/or drug substances which have a pKa value below about 5.5 such as in a range of from about 4 to about 5. The compositions have been designed in such a manner that two important requirements are obtained, namely i) that the pharmaceutical composition 10 releases the drug substance very fast under acidic conditions whereby the drug substance will become dissolved and, accordingly, available for absorption already almost immediately upon entrance into the stomach, and ii) that the me- chanical strength of a composition according to the invention is sufficiently high to withstand normal handling of a pharmaceutical composition and to enable the composition to be coated using traditional coating equipment well known by a person skilled in the art. A composition according to the invention is suitable for use in those cases in which a fast 15 onset of a therapeutic and/or prophylactic effect is desired, e.g. in connection with acute pain or mild to moderate pain. Accordingly, suitable therapeutically and/or propylactically active substances may inter alia be found in the class of drug substances denoted non-steroid anti-inflammatory drug substances (abbreviated in the following: NSAID sub- stances or NSAIDs). 20 DESCRIPTION OF THE INVENTION [0002] Pharmaceutical compositions designed to immediate release of a drug substance is known in the art. [0003] Generally, however, the rationale which lies behind the kind of compositions which have been described to enable an immediate release of a drug substance is to employ a traditional formulation approach (such as, e.g., i) plain 25 tablets which have a disintegration time in water of at the most about 30 min, ii) a traditionally formulated granulate or iii) loose powder of the drug substance itself. By doing so the immediate release part of the composition is intended to release the drug substance in a manner which corresponds to a plain tablet formulation or the like and the term "immediate" is in such a context intended to denote that the release of the drug substance is faster than the release from a sustained release composition. The development of the so-called SplashDose®, FlashDose® and Flashtabs® 30 are examples of pharmaceutical compositions wherein the focus has been to obtain a very fast disintegration time. Such formulations are suitable for use for drug substances which are readily soluble in the gastro-intestinal tract, but basically they do not solve the problems related to drug substances which have poor solubility characteristics. [0004] Especially in those cases where the drug substance has a low solubility in an acidic medium having a pH of from about 1 to about 3, i.e. a pH corresponding to the pH in the stomach, the traditional formulation approach will lead 35 to a pharmaceutical composition which has a suitable fast disintegration time but not necessarily a suitable fast dis- solution rate of the drug substance under acidic conditions, i.e. a plain tablet will rapidly disintegrates into granules but the dissolution of the drug substance from the composition and/or the disintegrated composition under acidic conditions may be unsuitable low due to the solubility properties of the drug substance itself. The availability of a drug substance with respect to absorption, i.e. entrance into the circulatory system, is dependant on the presence of the drug substance 40 on dissolved form as it is generally accepted that only dissolved substances are capable of passing the mucous mem- branes in the gastro-intestinal tract. Therefore, it is important that the dissolution of the drug substance is suitably fast even under acidic conditions in order to enable a fast and initial absorption so that a true fast or immediate therapeutic response is obtainable. [0005] For drug substances which are weak acids it is very important to ensure a proper bioavailability of the drug 45 substance already under acid conditions in order to achieve a true rapid therapeutic effect. However, the various ap- proaches disclosed with respect to achievement of a combination of a rapid effect do not seem to take all the above- mentioned factors into account and, hence, there is a need for developing compositions which enable a true rapid onset of the therapeutic effect. To this end, we have especially focused on compositions comprising a drug substance belonging to the class of drug substances normally denoted NSAIDs, but other drug substances having a low solubility 50 in acidic medium and/or a pKa below about 5.5 may as well be suitable for use in a composition according to the invention. [0006] Moreover, patients suffering from acute pain, mild to moderate pain and/or inflammatory conditions and/or related conditions very often require a dosage and a formulation which enable a fast onset of the therapeutic effect of the NSAID substances. The release from the dosage form must be safe, predictable and reliable. Furthermore, from 55 a technical point of view, the release rate and the release pattern of the active drug substance from the composition should not significantly change during the shelf-life of the composition. A change in the release rate and/or release pattern may have a significant impact on the in vivo performance of the composition. [0007] Quick release pharmaceutical compositions comprising dichlofenac sodium is disclosed in WO-A-96 14839. 2 EP 1 109 534 B1 The particle size of the dried product has a size distribution so that 90% of the particles is less than 30 µm. [0008] When testing prior art compositions intended for rapid release of the active drug substance (see e.g. Japanese patent No. 33491/90) the present inventors have revealed problems with respect to the release rate obtained and the robustness of the tablets. Thus, the development of a pharmaceutical composition which is suitable for rapid release 5 of the active substance seems surprisingly to be a balance of on the one hand to obtain a composition which is sufficient robust to withstand normal handling (i.e. to have a sufficient mechanical strength) and on the other hand to enable a fast release and dissolution of the active drug substance in an acidic aqueous medium. [0009] Thus, the purpose of the present invention is to provide a pharmaceutical composition for oral use, which is useful for a fast delivery of an active drug substance to the circulatory system upon administration. 10 [0010] In one aspect, the invention relates to a quick release pharmaceutical composition for oral administration comprising a therapeutically and/or prophylactically active substance defined by having a solubility of at the most about 0.1 % w/v in 0.1 N hydrochloric acid at room temperature and wherein the quick release composition further being based on a powder comprising the therapeutically and/or prophylactically active substance and having such a particle size that - when the powder is subjected to a sieve analysis - then at least about 90% w/w such as, at least about 92% 15 w/w, at least about 94% w/w, at least about 95% w/w, at least about 96% w/w, at least about 97% w/w, at least about 98% w/w or at least about 99% w/w of the particles passes through sieve 180 µm, the powder being contacted with an aqueous medium to form a particulate composition, which has such a particle size that - when the particulate com- position is subjected to a sieve analysis - then at least about 50% w/w such as, e.g., at least about 55% w/w.
Load more

Recommended publications
  • Eslicarbazepine Acetate: a New Improvement on a Classic Drug Family for the Treatment of Partial-Onset Seizures
    Drugs R D DOI 10.1007/s40268-017-0197-5 REVIEW ARTICLE Eslicarbazepine Acetate: A New Improvement on a Classic Drug Family for the Treatment of Partial-Onset Seizures 1 1 1 Graciana L. Galiana • Angela C. Gauthier • Richard H. Mattson Ó The Author(s) 2017. This article is an open access publication Abstract Eslicarbazepine acetate is a new anti-epileptic drug belonging to the dibenzazepine carboxamide family Key Points that is currently approved as adjunctive therapy and monotherapy for partial-onset (focal) seizures. The drug Eslicarbazepine acetate is an effective and safe enhances slow inactivation of voltage-gated sodium chan- treatment option for partial-onset seizures as nels and subsequently reduces the activity of rapidly firing adjunctive therapy and monotherapy. neurons. Eslicarbazepine acetate has few, but some, drug– drug interactions. It is a weak enzyme inducer and it Eslicarbazepine acetate improves upon its inhibits cytochrome P450 2C19, but it affects a smaller predecessors, carbamazepine and oxcarbazepine, by assortment of enzymes than carbamazepine. Clinical being available in a once-daily regimen, interacting studies using eslicarbazepine acetate as adjunctive treat- with a smaller range of drugs, and causing less side ment or monotherapy have demonstrated its efficacy in effects. patients with refractory or newly diagnosed focal seizures. The drug is generally well tolerated, and the most common side effects include dizziness, headache, and diplopia. One of the greatest strengths of eslicarbazepine acetate is its ability to be administered only once per day. Eslicar- 1 Introduction bazepine acetate has many advantages over older anti- epileptic drugs, and it should be strongly considered when Epilepsy is a common neurological disorder affecting over treating patients with partial-onset epilepsy.
    [Show full text]
  • Cambridgeshire and Peterborough Joint Prescribing Group MEDICINE REVIEW
    Cambridgeshire and Peterborough Joint Prescribing Group MEDICINE REVIEW Name of Medicine / Trimipramine (Surmontil®) Class (generic and brand) Licensed indication(s) Treatment of depressive illness, especially where sleep disturbance, anxiety or agitation are presenting symptoms. Sleep disturbance is controlled within 24 hours and true antidepressant action follows within 7 to 10 days. Licensed dose(s) Adults: For depression 50-75 mg/day initially increasing to 150-300 mg/day in divided doses or one dose at night. The maintenance dose is 75-150 mg/day. Elderly: 10-25 mg three times a day initially. The initial dose should be increased with caution under close supervision. Half the normal maintenance dose may be sufficient to produce a satisfactory clinical response. Children: Not recommended. Purpose of Document To review information currently available on this class of medicines, give guidance on potential use and assign a prescribing classification http://www.cambsphn.nhs.uk/CJPG/CurrentDrugClassificationTable.aspx Annual cost (FP10) 10mg three times daily: £6,991 25mg three times daily: £7,819 150mg daily: £7,410 300mg daily: £14,820 Alternative Treatment Options within Class Tricyclic Annual Cost CPCCG Formulary Classification Antidepressant (FP10) Amitriptyline (75mg) Formulary £36 Lofepramine (140mg) Formulary £146 Imipramine (75mg) Non-formulary £37 Clomipramine (75mg) Non-formulary £63 Trimipramine (75mg). TBC £7,819 Nortriptyline (75mg) Not Recommended (pain) £276 Doxepin (150mg) TBC £6,006 Dosulepin (75mg) Not Recommended (NICE DO NOT DO) £19 Dosages are based on possible maintenance dose and are not equivalent between medications Recommendation It is recommended to Cambridgeshire and Peterborough CCG JPG members and through them to local NHS organisations that the arrangements for use of trimipramine are in line with restrictions agreed locally for drugs designated as NOT RECOMMENDED:.
    [Show full text]
  • CBCS SYLLABUS) SUBJECT-BPH C 801 T-Pharmaceutical Chemistry III MULTIPLE CHOICE QUESTIONS: PRACTICE QUESTION BANK
    FINAL YEAR UNIVERSITY EXAMINATION 2019-2020 Final Year B.Pharm. Semester VIII (CBCS SYLLABUS) SUBJECT-BPH_C_801_T-Pharmaceutical Chemistry III MULTIPLE CHOICE QUESTIONS: PRACTICE QUESTION BANK SET-I Q. 1 Which is the correct IUPAC name for the following structure? A] 5-chloro-2-(methylamino)-5-phenyl-3H-1,4-benzodiazepine B] 7-chloro-2-(methylamino)-5-pyridinyl-3H-1,4-benzodiazepine-4-oxide C] 7-chloro-2-(ethylamino)-5-phenyl-3H-1,5-benzodiazepine D] 7-chloro-2-(methylamino)-5-phenyl-3H-1,4-benzodiazepine-4-oxide Q. 2 Which of the following is long acting sedative hypnotic? A] Diazepam B] Alprazolam C] Temazepam D] Imipramine Q. 3 Name of oxide derivative used as sedative hypnotic is A] Diazepam B] Chlordiazepoxide C]Nitazepam D] Ramelteon Q. 4 With respect to the following general structure which is the correctstatement ? A] X must be electropositive substituent for optimum activity B] X must be aromatic ring for optimum activity C] X must be electronegative substituent for optimum activity D] X must be H for optimum activity Q. 5 Which is the incorrect statement with respect to structure given in Q. 4 A] Ring C is ortho substituted with electron withdrawing group for optimum activity B] Ring C when para substituted increases activity C] Ring C is diortho substituted with electron withdrawing group for optimum activity D] Ring C when para substituted decreases activity Q. 6 What is the starting material for synthesis of Piroxicam (structure given below) A] B] C] D] Q. 7 Which one of the following is Cytokine inhibitor? A] Abatacept B] Fluoxetine C] Propranolol D]Aldosterone Q.
    [Show full text]
  • Microfilms International 300 N
    Synthesis and monoamine uptake inhibiting properties of perisubstituted tricyclic compounds Item Type text; Thesis-Reproduction (electronic) Authors Peters, Jennifer Margaret, 1956- Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 07/10/2021 13:32:03 Link to Item http://hdl.handle.net/10150/291828 INFORMATION TO USERS This reproduction was made from a copy of a document sent to us for microfilming. While the most advanced technology has been used to photograph and reproduce this document, the quality of the reproduction is heavily dependent upon the quality of the material submitted. The following explanation of techniques is provided to help clarify markings or notations which may appear on this reproduction. 1. The sign or "target" for pages apparently lacking from the document photographed is "Missing Page(s)". If it was possible to obtain the missing page(s) or section, they are spliced into the film along with adjacent pages. This may have necessitated cutting through an image and duplicating adjacent pages to assure complete continuity. 2. When an image on the film is obliterated with a round black mark, it is an indication of either blurred copy because of movement during exposure, duplicate copy, or copyrighted materials that should not have been filmed. For blurred pages, a good image of the page can be found in the adjacent frame.
    [Show full text]
  • Specific Adsorption Sites and Conditions Derived
    www.nature.com/scientificreports OPEN Specifc adsorption sites and conditions derived by thermal decomposition of activated carbons and adsorbed carbamazepine Daniel Dittmann 1,2*, Paul Eisentraut1, Caroline Goedecke1, Yosri Wiesner1, Martin Jekel2, Aki Sebastian Ruhl2,3 & Ulrike Braun1 The adsorption of organic micropollutants onto activated carbon is a favourable solution for the treatment of drinking water and wastewater. However, these adsorption processes are not sufciently understood to allow for the appropriate prediction of removal processes. In this study, thermogravimetric analysis, alongside evolved gas analysis, is proposed for the characterisation of micropollutants adsorbed on activated carbon. Varying amounts of carbamazepine were adsorbed onto three diferent activated carbons, which were subsequently dried, and their thermal decomposition mechanisms examined. The discovery of 55 diferent pyrolysis products allowed diferentiations to be made between specifc adsorption sites and conditions. However, the same adsorption mechanisms were found for all samples, which were enhanced by inorganic constituents and oxygen containing surface groups. Furthermore, increasing the loadings led to the evolution of more hydrated decomposition products, whilst parts of the carbamazepine molecules were also integrated into the carbon structure. It was also found that the chemical composition, especially the degree of dehydration of the activated carbon, plays an important role in the adsorption of carbamazepine. Hence, it is thought that the adsorption sites may have a higher adsorption energy for specifc adsorbates, when the activated carbon can then potentially increase its degree of graphitisation. Increasing amounts of pharmaceuticals enter the water bodies and are detected all over the world1–3. Many of them are persistent and may accumulate within water cycles4–6.
    [Show full text]
  • New Zealand Data Sheet
    1 PARNATE tranylcypromine film-coated tablets 10 mg New Zealand Data Sheet 1 PARNATE® (10 MG FILM-COATED TABLETS) PARNATE 10 mg film-coated tablets. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Parnate 10 mg film-coated tablets: each tablet contains tranylcypromine sulfate equivalent to 10 mg of tranylcypromine. Excipients with known effect: each tablet contains sucrose 6 mg. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Parnate 10 mg film-coated tablets contain "geranium rose" coloured, biconvex, film-coated tablets. 4 CLINICAL PARTICULARS 4.1 Therapeutic indications Parnate is indicated for the treatment of symptoms of depressive illness especially where treatment with other types of anti-depressants has failed. It is not recommended for use in mild depressive states resulting from temporary situational difficulties. 4.2 Dose and method of administration Adults Begin with 20 mg a day given as 10 mg in the morning and 10 mg in the afternoon. If there is no satisfactory response after two weeks, add one more tablet at midday. Continue this dosage for at least a week. A dosage of 3 tablets a day should only be exceeded with caution. When a satisfactory response is established, dosage may be reduced to a maintenance level. Some patients will be maintained on 20 mg per day, some will need only 10 mg daily. If no improvement occurs, continued administration is unlikely to be beneficial. 1 2 PARNATE tranylcypromine film-coated tablets 10 mg When given together with a tranquilliser, the dosage of Parnate is not affected. When the medicine is given concurrently with electroconvulsive therapy, the recommended dosage is 10 mg twice a day during the series and 10 mg a day afterwards as maintenance therapy.
    [Show full text]
  • Journal of Central Nervous System Disease a Review Of
    Journal of Central Nervous System Disease OPEN ACCESS Full open access to this and thousands of other papers at EXPERT REVIEW http://www.la-press.com. A Review of Eslicarbazepine Acetate for the Adjunctive Treatment of Partial-Onset Epilepsy Rajinder P. Singh and Jorge J. Asconapé Department of Neurology, Stritch School of Medicine, Loyola University Medical Center, Maywood, Illinois 60153, USA. Corresponding author email: [email protected] Abstract: Eslicarbazepine acetate (ESL) is a novel antiepileptic drug indicated for the treatment of partial-onset seizures. Structurally, it belongs to the dibenzazepine family and is closely related to carbamazepine and oxcarbazepine. Its main mechanism of action is by blocking the voltage-gated sodium channel. ESL is a pro-drug that is rapidly metabolized almost exclusively into S-licarbazepine, the biologically active drug. It has a favorable pharmacokinetic and drug-drug interaction profile. However, it may induce the metabolism of oral contraceptives and should be used with caution in females of child-bearing age. In the pre-marketing placebo-controlled clinical trials ESL has proven effective as adjunctive therapy in adult patients with refractory of partial-onset seizures. Best results were observed on a single daily dose between 800 and 1200 mg. In general, ESL was well tolerated, with most common dose-related side effects including dizziness, somnolence, headache, nausea and vomiting. Hyponatremia has been observed (0.6%–1.3%), but the incidence appears to be lower than with the use of oxcarbazepine. There is very limited information on the use of ESL in children or as monotherapy. Keywords: eslicarbazepine, licarbazepine, dibenzazepine, voltage-gated sodium channel, partial-onset seizures, epilepsy Journal of Central Nervous System Disease 2011:3 179–187 doi: 10.4137/JCNSD.S4888 This article is available from http://www.la-press.com.
    [Show full text]
  • Effects of Antipsychotic Treatment on Haematological Parameters of Psychotic Patients in Tertiary Care Hospital of India
    Original Research Article http://doi.org/10.18231/j.ijcaap.2019.027 Effects of antipsychotic treatment on haematological parameters of psychotic patients in tertiary care hospital of India Nutanbala N. Goswami1*, Jignesh Gondliya2, Alpeshpuri P. Goswami3 1,3Associate Professor, 2Senior Resident, 1Dept. of Pharmacology, 2,3Dept. of Pathology, Government Medical college, Bhavnagar, Gujarat, India *Corresponding Author: Nutanbala N. Goswami Email: [email protected] Abstract Introduction/Aim of study: Use of some antipsychotic agents results in haematological changes like leukopenia, neutropenia, thrombocytopenia, anaemia, Leukocytosis, thrombocytosis which may present a major problem for the management of psychotic patients. Material and Methods: Twenty four patients on therapy with antipsychotic drugs for a minimum period of three months were recruited for study for haematological changes at tertiary care Hospital of India. The study was conducted between March and august, 2019. Results: Out of 24 cases, 1 patient developed neutropenia (4.16%), and 01 patient developed anaemia (4.16%) within 3 month of treatment without any haematological disease. Conclusion: The significant reduction in blood cell count observed associated with antipsychotic agents especially neutropenia. An appropriate monitoring strategy should be used for clozapine and other antipsychotic drug to minimize the adverse drug reaction and early shift of treatment. Keywords: Antipsychotic drugs, Haematological parameters, Neutropenia. Introduction olanzipine and quetiapine
    [Show full text]
  • Novel Approaches to Enhancing Selectivity and Efficiency in Microscale Liquid Chromatography
    AN ABSTRACT OF THE DISSERTATION OF Patrick T. Vallano for the degree of Doctor of Philosophy in Chemistry presented on March 6, 2001. Title: Novel Approaches to Enhancing Selectivity and Efficiency in Microscale Liquid Chromatography. Abstract approved: Redacted for Privacy Vincent T. Remcho For a number of reasons, miniaturization of chromatographic columns has been a general trend over the past three decades. Methods designed to enhance selectivity and efficiency can offer improved separation power and speed, expanding on the advantages of miniaturized columns. This dissertation describes novel approaches in this direction, focusing on two areas: the development of affinity-type sorbents for capillary HPLC derived from molecular imprinted polymers (MIPs) and the study of perfusive electroosmosotic flow (EOF) and its effect on efficiency in capillary electrochromatography (CEC). MIPs are synthetic polymers capable of selectively binding a template molecule incorporated prior to polymerization. MIPs prepared using nortripyline,a tricyclic antidepressant drug, were employed to screen a simulated chemical library, consisting of a series of structural analogs and related compounds. A parameterwas introduced to quantify the selective retention of the analytes. Library compounds containing the maj or structural features of the template (ring structure and pendant 2° amine) exhibited the highest affinity for the MIP. The use of macroporous packings under conditions of electroosmotic perfusion can result in improved chromatographic efficiencies. In this work, the performance of CEC columns packed with particles having different nominal pore diameters was investigated. The results indicate that perfusive EOF can yield significant gains in efficiency and speed, especially when wide pore packings and dilute buffers are employed.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,771,972 B2 Salamone Et Al
    US00877 1972B2 (12) United States Patent (10) Patent No.: US 8,771,972 B2 SalamOne et al. (45) Date of Patent: Jul. 8, 2014 (54) CLOZAPINE IMMUNOASSAY (56) References Cited (75) Inventors: Salvatore J. Salamone, Stockton, NJ U.S. PATENT DOCUMENTS (US); Jodi Blake Courtney, 6, 197,764 B1 3/2001 Bradley et al. Doylestown, PA (US); Howard Sard, 2006/02231.34 A1* 10, 2006 Salamone et al. ........... 435,792 Arlington, MA (US); Christopher 2006/0252744 A1 11/2006 Burstein Spedaliere, Allentown, PA (US) 2009, 0215082 A1 8/2009 Salamone et al. 2012/030 1973 A1* 11/2012 Salamone et al. ............ 436,501 (73) Assignee: Saladax Biomedical Inc., Bethlehem, OTHER PUBLICATIONS PA (US) Ming et al., “Therapeutic drug monitoring of clozapine and (*) Notice: Subject to any disclaimer, the term of this norclozapine in human serum using ultra-performance liquid chro patent is extended or adjusted under 35 matography-tandem mass spectrometry.” J. Anal. Toxicol., 2009, vol. U.S.C. 154(b) by 189 days. 33, No. 4, pp. 198-203.* Mendoza et al., “N-Desmethylclozapine: Is There Evidence for its Antipsychotic Potential?.” Clin. Neuropharm., 2009, vol. 32, issue 3, (21) Appl. No.: 13/186,147 pp. 154-157.* Gardner et al., “A Comparison of the Covalent Binding of Clozapine (22) Filed: Jul.19, 2011 and Olanzapine to Human Neutrophils. In Vitro and In Vivo.” Mol. Pharmacol., 1998, vol. 53, pp. 999-1008.* (65) Prior Publication Data Liu et al., "Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to the cells,” J. Pharm. US 2012/O3O1974 A1 Nov.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Tardive Akathisia
    HEALTH & SAFETY: PSYCHIATRIC MEDICATIONS Tardive Akathisia FACT SHEET Tardive Akathisia BQIS Fact Sheets provide a general overview on topics important to supporting an individual’s health and safety and to improving their quality of life. This document provides general information on the topic and is not intended to replace team assessment, decision-making, or medical advice. This is the ninth of ten Fact Sheets regarding psychotropic medications. Intended Outcomes Individuals will understand the symptoms, common causes, and treatment of tardive akathisia. Definitions Akathisia: A movement disorder characterized by motor restlessness/a feeling of inner restlessness with a compelling need to be moving. Tardive akathisia: A severe prolonged form of akathisia which may persist after stopping the medica- tion causing the symptoms. Facts • Akathisia is: – the most common drug induced movement disorder. – a side effect of medication. – most often caused by antipsychotic medications that block dopamine. • Medications with akathisia as a potential side effect include: – Benzisothiazole (ziprasidone) – Benzisoxazole (iloperidone) – Butyrophenones (haloperidol, droperidol) – Calcium channel blockers (flunarizine, cinnarizine) – Dibenzazepine (loxapine, asenapine) – Dibenzodiazepine (clozapine, quetiapine) – Diphenylbutylpiperidine (pimozide) – Indolones (molindone) – Lithium – Phenothiazines (chlorpromazine, triflupromazine, thioridazine, mesoridazine, trifluoperazine, prochlorperazine, perphenazine, fluphenazine, perazine) Bureau of Quality Improvement
    [Show full text]